Receive the latest updates from Matrix Medical in real time to understand product information.

Recently, Matrix Medical announced the completion of a Pre-A round of financing worth tens of millions of yuan.This round of financing is led by Hetang Venture Capital Fund and co invested by old shareholder Tai Yu Investment. It is reported that the funds raised in this round of financing will be used to support the clinical validation of the company's natural vascular stent series products. Among them, the coronary natural vascular stent will start clinical trials in the near future. At the same time, Matrix Medical will further increase research and development investment and launch more original devices around the clinical vascular disease treatment needs.

In September of this year, Juzheng Medical and Seno Shenchang reached a strategic cooperation on their vascular occlusion device products and vascular intervention business, further accelerating product conversion and improving business layout. Since its establishment in 2021, Matrix Medical has developed rapidly,“First place in the Greater Bay Area Special Competition of the 5th China Medical Device Innovation and Entrepreneurship Competition in 2022, and first place in the VINNOVA 2023 Innovation Competition of the Vascular Innovation Forum”Has made a strong appearance in the vascular intervention market with multiple honors. In the two years of increasingly cautious investment in the medical field, following its angel round financing of tens of millions of yuan in early 2022, Matrix Medical has received another round of funding from well-known institutions. At the same time, the company's multiple product lines are rapidly advancing, and the core product, vascular occluder, has completed all clinical trials. The natural vascular stent product is about to enter the clinical validation stage.

As the source of innovation and the terminal of application, Ji Peihong, the founder of Matrix Medical, has a clear understanding of the company's positioning: "In building a technology innovation achievement transformation platform, we not only need to match advanced technology with clinical needs, but also provide scientific transformation paths, integrate transformation resources, and provide industrialization support. True technological innovation comes from scientists, and we hope to help them find effective applications of innovative technology in clinical practice, crossing the 'death valley' from scientific research to industrialization

After the completion of this round of financing, at the product level, Matrix Medical will rely on the company's underlying material technology platform and scientific research resources to independently develop or collaborate on the transformation of more innovative products needed in clinical practice. Currently, products such as special function balloons and special function catheters are rapidly advancing, and multiple products are expected to obtain certification next year; At the team level, the company will continue to expand its research and development, production, and marketing teams, and strengthen its product development full chain service capabilities. In addition, the company will gradually carry out clinical and market-oriented operations overseas.